About us

 

GenoGla Diagnostics was created as a spin-off of the University of Algarve, Faro, Portugal.

 

GenoGla was first created to serve as a platform to commercially explore the newly developed products and technologies that are included in an international patent application (PCT/PT2009000046; U. S. Patent 61/136.315 filled in 27 August 2008) as well as to pursue research and explore new findings and patents originating from collaboration research contracts (e.g. on bone and cardiovascular health, skin care, cancer and diagnostics).

 

 

Team

 

Dina Simes

PhD

Chief Executive Officer (CEO) & Co-Managing Director


Msc in cellular chemistry in 1998, PhD in Chemistry-Biochemistry – University of Algarve, since 2003 Full Professor of Biochemistry at FCT-University of Algarve, Researcher and head group leader at CCMAR (Research group-Functional Biochemistry and Proteomics). Co-founder of GenoGla Diagnostics in May 2009.

 

Carla São Bento Viegas

PhD

Chief Operating Officer (COO) & Co-Managing Director

 

PhD in Biochemistry – Molecular and Cellular Biology, University of Algarve. Carla is a senior researcher at CCMAR (Centre of Marine Sciences, University of Algarve), working within the Functional Biochemistry and Proteomics group. She co-founded GenoGla Diagnostics in May 2009 and currently serves as Chief Operating Officer and co-managing director. Her expertise bridges academic research and biotechnology innovation, with a focus on molecular diagnostics, protein biochemistry, and translational applications in human health.

 

Aim

 

The aim of the company is the commercialization of the newly developed IP knowledge, products and technologies directly or via collaborations, joint ventures, royalties or research contracts.

  

Another goal of this company is to offer specialized services based both on our IP methods and tools and also on our own research in the area of Proteomics and Molecular Biology.

 

One important goal is to establish a diagnostic test based on circulating GRP, which is a patented system (PCT/PT2009000046). This assay could be used to monitor, among others, cardiovascular disease states, by following concentrations of specific biochemical markers in blood.

  

The IP tools and kits are also intended for use in biomedical research in the area of calcification related diseases that precludes its future use in diagnostics, prognostic and also for monitoring treatments.

 

 

 

Company
Research and development
Products
Services
Collaborations
References
Contact

 

Copyright © 2025

GenoGla - Research and diagnostics

genogla@genogla.com